Drugs.com has information about the side effects of Tradjenta.

There is side effect information in this document.The brand name may not apply to some of the forms listed on this page.

There are more frequent side effects.Below is a list of adverse effects.

linagliptin may cause some unwanted effects along with its needed effects.Some of these side effects may need medical attention if they occur.

If there are any of the following side effects, you need to check with your doctor.

There are some side effects of linagliptin that do not need medical attention.As your body adjusts to the medicine, these side effects may go away.Some of these side effects can be prevented or reduced by your health care professional.

Check with your health care professional if any of the side effects continue or if you have questions about them.

In clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin.3 more cases of pancreatitis were reported after the completion of clinical trials for those receiving linagliptin.Reports of acute pancreatitis, including deaths, have been received.The most common adverse event reported was nasopharyngitis.Serious hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions have been reported postmarketing in patients treated with this drug.The reactions have happened within the first 3 months.The incidence of hypoglycemia in patients treated with this drug as monotherapy, or in combination with metformin or pioglitazone, was similar to the incidence observed in placebo-treated patients.In combination with a sulfonylurea, the incidence of hypoglycemia was almost 23% compared to 15% in those receiving placebo.The incidence of hypoglycemia was similar to placebo as an add-on to stableinsulin therapy.Postmarketing reports of hypoglycemia, hypertriglyceridemia and increased uric acid.The case usually recovered with a systemic immunosuppressive treatment.Thirty-three cases of severe arthr were reported between October 2006 and December 2013).One or more dipeptidyl peptidase-4 (DPP-4) inhibitor was used in each case.10 patients were hospitalized due to disabling joint pain, as a result of substantial reduction in prior activity level.Within 1 month of starting therapy, symptoms appeared in 22 cases, and in 23 cases symptoms were resolved less than a month after stopping therapy.There were 8 cases where a positive rechallenge was reported.saxagliptin had the most cases reported, followed by linagliptin and vildagLiptin.The nervous system is 1% to 10%.Product information.The name of the drug is linagliptin.Boehringer Ingelheim is in Connecticut."Australian Product Information" is a trademark of Cerner Multum, Inc.There is a new date O03.There is a summary of product characteristics in the UK.O4/20/2019.The FDA warns that the drugs may cause joint pain.The URL is http://www.fda.gov.Drug Images Drug Interactions Pricing & Coupons En Espaol 54 Reviews Drug class: dipeptidyl peptidase 4Some side effects may not be reported.You can report them to the FDA.If (!document.querySelectorAll) return, what do you think about refs?refs.split(',')Return false, "References relevant to chosen section."

In clinical trials, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure in patients receiving linagliptin.3 more cases of pancreatitis were reported after the completion of clinical trials for those receiving linagliptin.Reports of acute pancreatitis, including deaths, have been received.Ref

There have been reports of serious hypersensitivity reactions in patients treated with this drug.The reactions have happened within the first 3 months.Ref

In comparison to placebo-treated patients, the incidence of hypoglycemia in patients treated with this drug as monotherapy or in combination with metformin or pioglitazone was similar.In combination with a sulfonylurea, the incidence of hypoglycemia was almost 23% compared to 15% in those receiving placebo.The incidence of hypoglycemia was similar to placebo as an add-on to stableinsulin therapy.Ref

There have been reports of bullous pemphigoid requiring hospitalization with dipeptidyl peptidase-4 use.The case usually recovered with a systemic immunosuppressive treatment.Ref

Thirty-three cases of severe arthralgia have been reported to the FDA.One or more dipeptidyl peptidase-4 (DPP-4) inhibitor was used in each case.10 patients were hospitalized due to disabling joint pain, as a result of substantial reduction in prior activity level.Within 1 month of starting therapy, symptoms appeared in 22 cases, and in 23 cases symptoms were resolved less than a month after stopping therapy.There were 8 cases where a positive rechallenge was reported.saxagliptin had the most cases reported, followed by linagliptin and vildagLiptin.Ref

4.The FDA warns that the drugs may cause joint pain.The URL is http://www.fda.gov.August 28, 2015:

To ensure the information on this page applies to your personal circumstances, always consult your healthcare provider.